stockrow
Friday 6 November 2026
Export ADPT’s income statement to Excel — free account
Adaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −70.8%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
28.00
1.17
+4.36%
Follow ADPT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 6 | 6 |
+8 more TTM periods Free account |
| (36.34%) | (38.68%) | (23.97%) | (27.84%) | ||
| (12.02%) | (11.23%) | (9.77%) | (11.31%) | ||
ROIC |
(13.68%) | (16.57%) | (494.38%) | 0.00% | |
Return on Tangible Assets |
(21.92%) | (17.62%) | (21.09%) | (24.35%) | |
Average Days of Receivables |
81.66 | 58.66 | 59.70 | 66.37 | |
Free Cash Flow per Share |
(0.05) | (0.15) | (0.19) | (0.32) | |
Free Cash Flow |
(8.82) | (24.03) | (29.53) | (48.94) | |
Capital Expenditures |
(4.54) | (3.02) | (2.50) | (2.96) | |
| Other line items | |||||
Cash ROIC |
(1.08%) | (2.90%) | (6.67%) | (10.83%) | |
Accounts Receivable Turnover |
5.35 | 6.57 | 6.43 | 6.01 | |
Accounts Payable Turnover |
9.17 | 12.39 | 9.15 | 10.39 | |
Inventory Turnover |
7.71 | 7.96 | 7.35 | 7.82 | |
Average Days of Payables |
30.93 | 25.42 | 48.02 | 33.08 | |
Days of Inventory on Hand |
47.64 | 50.91 | 55.96 | 50.23 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
27.91% | 28.63% | 31.55% | 33.85% | |
Selling, General and Administrative Expense of Revenue |
61.85% | 58.55% | 58.95% | 60.39% | |
Share Based Compensation of Revenue |
15.49% | 15.91% | 17.35% | 18.59% | |
Interest Coverage |
(5.33) | (3.25) | (3.97) | (4.85) | |
Operating CF/Net income |
0.06 | 0.33 | 0.54 | 0.77 | |
Depreciation/Fixed assets |
0.51 | 0.51 | 0.50 | 0.45 | |
Capex/Depreciation |
(0.32) | (0.20) | (0.16) | (0.19) | |
Revenue per Share |
1.86 | 1.93 | 1.90 | 1.83 | |
Operating CF per Share |
(0.03) | (0.13) | (0.17) | (0.30) | |
Capex per Share |
(0.03) | (0.02) | (0.02) | (0.02) | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026